context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
and $ 131 million, respectively. | text | 131 | monetaryItemType | text: <entity> 131 </entity> <entity type> monetaryItemType </entity type> <context> and $ 131 million, respectively. </context> | us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss |
16 additional SHOP facilities for $ 230 million | text | 230 | monetaryItemType | text: <entity> 230 </entity> <entity type> monetaryItemType </entity type> <context> 16 additional SHOP facilities for $ 230 million </context> | us-gaap:ProceedsFromSaleOfBuildings |
in January 2021, the Company provided the buyer with financing of $ 150 million. The remainder of the sales price was received in cash at the time of sale. The financing is secured by the buyer’s equity ownership in each property. Upon maturity in January 2023, the borrower did not make the required principal repayment... | text | 102 | monetaryItemType | text: <entity> 102 </entity> <entity type> monetaryItemType </entity type> <context> in January 2021, the Company provided the buyer with financing of $ 150 million. The remainder of the sales price was received in cash at the time of sale. The financing is secured by the buyer’s equity ownership in each property. Upon... | us-gaap:ProceedsFromCollectionOfLoansReceivable |
in January 2021, the Company provided the buyer with financing of $ 150 million. The remainder of the sales price was received in cash at the time of sale. The financing is secured by the buyer’s equity ownership in each property. Upon maturity in January 2023, the borrower did not make the required principal repayment... | text | 11 | percentItemType | text: <entity> 11 </entity> <entity type> percentItemType </entity type> <context> in January 2021, the Company provided the buyer with financing of $ 150 million. The remainder of the sales price was received in cash at the time of sale. The financing is secured by the buyer’s equity ownership in each property. Upon m... | us-gaap:LoansReceivableBasisSpreadOnVariableRate |
in January 2021, the Company provided the buyer with financing of $ 150 million. The remainder of the sales price was received in cash at the time of sale. The financing is secured by the buyer’s equity ownership in each property. Upon maturity in January 2023, the borrower did not make the required principal repayment... | text | 6.0 | percentItemType | text: <entity> 6.0 </entity> <entity type> percentItemType </entity type> <context> in January 2021, the Company provided the buyer with financing of $ 150 million. The remainder of the sales price was received in cash at the time of sale. The financing is secured by the buyer’s equity ownership in each property. Upon ... | us-gaap:LoansReceivableBasisSpreadOnVariableRate |
in January 2021, the Company provided the buyer with financing of $ 150 million. The remainder of the sales price was received in cash at the time of sale. The financing is secured by the buyer’s equity ownership in each property. Upon maturity in January 2023, the borrower did not make the required principal repayment... | text | 7.0 | percentItemType | text: <entity> 7.0 </entity> <entity type> percentItemType </entity type> <context> in January 2021, the Company provided the buyer with financing of $ 150 million. The remainder of the sales price was received in cash at the time of sale. The financing is secured by the buyer’s equity ownership in each property. Upon ... | us-gaap:LoansReceivableBasisSpreadOnVariableRate |
In conjunction with the sale of 59 outpatient medical buildings for $ 674 million in July 2024 and the 2 outpatient medical buildings for $ 23 million in November 2024 (see Note 5), the Company provided the buyer with a mortgage loan secured by the real estate sold for $ 405 million and $ 14 million, respectively. The ... | text | 674 | monetaryItemType | text: <entity> 674 </entity> <entity type> monetaryItemType </entity type> <context> In conjunction with the sale of 59 outpatient medical buildings for $ 674 million in July 2024 and the 2 outpatient medical buildings for $ 23 million in November 2024 (see Note 5), the Company provided the buyer with a mortgage loan s... | us-gaap:ProceedsFromSaleOfBuildings |
In conjunction with the sale of 59 outpatient medical buildings for $ 674 million in July 2024 and the 2 outpatient medical buildings for $ 23 million in November 2024 (see Note 5), the Company provided the buyer with a mortgage loan secured by the real estate sold for $ 405 million and $ 14 million, respectively. The ... | text | 23 | monetaryItemType | text: <entity> 23 </entity> <entity type> monetaryItemType </entity type> <context> In conjunction with the sale of 59 outpatient medical buildings for $ 674 million in July 2024 and the 2 outpatient medical buildings for $ 23 million in November 2024 (see Note 5), the Company provided the buyer with a mortgage loan se... | us-gaap:ProceedsFromSaleOfBuildings |
In conjunction with the sale of 59 outpatient medical buildings for $ 674 million in July 2024 and the 2 outpatient medical buildings for $ 23 million in November 2024 (see Note 5), the Company provided the buyer with a mortgage loan secured by the real estate sold for $ 405 million and $ 14 million, respectively. The ... | text | 1 | monetaryItemType | text: <entity> 1 </entity> <entity type> monetaryItemType </entity type> <context> In conjunction with the sale of 59 outpatient medical buildings for $ 674 million in July 2024 and the 2 outpatient medical buildings for $ 23 million in November 2024 (see Note 5), the Company provided the buyer with a mortgage loan sec... | us-gaap:ProceedsFromLoanOriginations1 |
In January 2025, the Company received full repayment of the outstanding balance of one $ 15 million secured loan with an original maturity of July 2027. As a result of this repayment, the $ 85 million of remaining commitments as of December 31, 2024 to fund additional loans for outpatient medical capital expenditure pr... | text | 15 | monetaryItemType | text: <entity> 15 </entity> <entity type> monetaryItemType </entity type> <context> In January 2025, the Company received full repayment of the outstanding balance of one $ 15 million secured loan with an original maturity of July 2027. As a result of this repayment, the $ 85 million of remaining commitments as of Dece... | us-gaap:ProceedsFromCollectionOfLoansReceivable |
In February 2023, the Company received full repayment of the outstanding balance of one $ 35 million secured loan. | text | 35 | monetaryItemType | text: <entity> 35 </entity> <entity type> monetaryItemType </entity type> <context> In February 2023, the Company received full repayment of the outstanding balance of one $ 35 million secured loan. </context> | us-gaap:ProceedsFromCollectionOfLoansReceivable |
In April 2023, the Company received full repayment of the outstanding balance of one $ 14 million secured loan. | text | 14 | monetaryItemType | text: <entity> 14 </entity> <entity type> monetaryItemType </entity type> <context> In April 2023, the Company received full repayment of the outstanding balance of one $ 14 million secured loan. </context> | us-gaap:ProceedsFromCollectionOfLoansReceivable |
In May 2023, the Company received full repayment of two outstanding secured loans with an aggregate balance of $ 12 million. | text | 12 | monetaryItemType | text: <entity> 12 </entity> <entity type> monetaryItemType </entity type> <context> In May 2023, the Company received full repayment of two outstanding secured loans with an aggregate balance of $ 12 million. </context> | us-gaap:ProceedsFromCollectionOfLoansReceivable |
Also in May 2023, the interest rate on one secured loan with an outstanding balance of $ 21 million was converted from a variable rate based on LIBOR to a variable rate based on Term SOFR (plus a 10 basis point adjustment related to SOFR transition). In October 2023, the Company received full repayment of the outstandi... | text | 21 | monetaryItemType | text: <entity> 21 </entity> <entity type> monetaryItemType </entity type> <context> Also in May 2023, the interest rate on one secured loan with an outstanding balance of $ 21 million was converted from a variable rate based on LIBOR to a variable rate based on Term SOFR (plus a 10 basis point adjustment related to SOF... | us-gaap:ProceedsFromCollectionOfLoansReceivable |
In May 2022, the Company received full repayment of the outstanding balance of one $ 2 million secured loan. | text | 2 | monetaryItemType | text: <entity> 2 </entity> <entity type> monetaryItemType </entity type> <context> In May 2022, the Company received full repayment of the outstanding balance of one $ 2 million secured loan. </context> | us-gaap:ProceedsFromCollectionOfFinanceReceivables |
In November 2022, the Company received full repayment of the outstanding balance of one $ 1 million mezzanine loan. | text | 1 | monetaryItemType | text: <entity> 1 </entity> <entity type> monetaryItemType </entity type> <context> In November 2022, the Company received full repayment of the outstanding balance of one $ 1 million mezzanine loan. </context> | us-gaap:ProceedsFromCollectionOfFinanceReceivables |
In December 2022, the Company extended the maturity dates of four secured loans with an aggregate outstanding balance of $ 61 million, originally scheduled to mature in December 2022, by one year to December 2023. In connection with the extensions, the interest rates on the loans were increased to a variable rate based... | text | 10 | percentItemType | text: <entity> 10 </entity> <entity type> percentItemType </entity type> <context> In December 2022, the Company extended the maturity dates of four secured loans with an aggregate outstanding balance of $ 61 million, originally scheduled to mature in December 2022, by one year to December 2023. In connection with the ... | us-gaap:LoansReceivableBasisSpreadOnVariableRate |
In December 2022, the Company extended the maturity dates of four secured loans with an aggregate outstanding balance of $ 61 million, originally scheduled to mature in December 2022, by one year to December 2023. In connection with the extensions, the interest rates on the loans were increased to a variable rate based... | text | 8.5 | percentItemType | text: <entity> 8.5 </entity> <entity type> percentItemType </entity type> <context> In December 2022, the Company extended the maturity dates of four secured loans with an aggregate outstanding balance of $ 61 million, originally scheduled to mature in December 2022, by one year to December 2023. In connection with the... | us-gaap:LoansReceivableBasisSpreadOnVariableRate |
In December 2022, the Company extended the maturity dates of four secured loans with an aggregate outstanding balance of $ 61 million, originally scheduled to mature in December 2022, by one year to December 2023. In connection with the extensions, the interest rates on the loans were increased to a variable rate based... | text | 10.5 | percentItemType | text: <entity> 10.5 </entity> <entity type> percentItemType </entity type> <context> In December 2022, the Company extended the maturity dates of four secured loans with an aggregate outstanding balance of $ 61 million, originally scheduled to mature in December 2022, by one year to December 2023. In connection with th... | us-gaap:LoansReceivableBasisSpreadOnVariableRate |
For certain residents that qualify, CCRCs may offer to lend residents the necessary funds to satisfy the entrance fee requirements so that they are able to move into a community while still continuing the process of selling their previous home. The loans are due upon sale of the resident’s previous home. At December 31... | text | 61 | monetaryItemType | text: <entity> 61 </entity> <entity type> monetaryItemType </entity type> <context> For certain residents that qualify, CCRCs may offer to lend residents the necessary funds to satisfy the entrance fee requirements so that they are able to move into a community while still continuing the process of selling their previo... | us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss |
and $ 43 million, respectively, of such notes receivable. | text | 43 | monetaryItemType | text: <entity> 43 </entity> <entity type> monetaryItemType </entity type> <context> and $ 43 million, respectively, of such notes receivable. </context> | us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss |
unconsolidated lab joint ventures in South San Francisco, California in which the Company holds a 70 % ownership percentage in each joint venture. These joint ventures have been aggregated herein due to similarity of the investments and operations. | text | 70 | percentItemType | text: <entity> 70 </entity> <entity type> percentItemType </entity type> <context> unconsolidated lab joint ventures in South San Francisco, California in which the Company holds a 70 % ownership percentage in each joint venture. These joint ventures have been aggregated herein due to similarity of the investments and ... | us-gaap:EquityMethodInvestmentOwnershipPercentage |
Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the remaining 80 % interest in one of the two properties that were in the Ventures IV uncon... | text | 20 | percentItemType | text: <entity> 20 </entity> <entity type> percentItemType </entity type> <context> Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the rema... | us-gaap:EquityMethodInvestmentOwnershipPercentage |
Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the remaining 80 % interest in one of the two properties that were in the Ventures IV uncon... | text | 67 | percentItemType | text: <entity> 67 </entity> <entity type> percentItemType </entity type> <context> Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the rema... | us-gaap:EquityMethodInvestmentOwnershipPercentage |
Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the remaining 80 % interest in one of the two properties that were in the Ventures IV uncon... | text | 80 | percentItemType | text: <entity> 80 </entity> <entity type> percentItemType </entity type> <context> Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the rema... | us-gaap:EquityMethodInvestmentOwnershipPercentage |
Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the remaining 80 % interest in one of the two properties that were in the Ventures IV uncon... | text | one | integerItemType | text: <entity> one </entity> <entity type> integerItemType </entity type> <context> Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the rem... | us-gaap:NumberOfRealEstateProperties |
Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the remaining 80 % interest in one of the two properties that were in the Ventures IV uncon... | text | two | integerItemType | text: <entity> two </entity> <entity type> integerItemType </entity type> <context> Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the rem... | us-gaap:NumberOfRealEstateProperties |
Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the remaining 80 % interest in one of the two properties that were in the Ventures IV uncon... | text | 4 | monetaryItemType | text: <entity> 4 </entity> <entity type> monetaryItemType </entity type> <context> Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the rema... | us-gaap:PaymentsToAcquireEquityMethodInvestments |
$ 49 million, respectively, is primarily attributable to the difference between the amount for which the Company purchased its interest in certain joint ventures and the historical carrying value of the net assets of the related joint ventures and capitalized interest related to the redevelopment activities at the Sout... | text | 49 | monetaryItemType | text: <entity> 49 </entity> <entity type> monetaryItemType </entity type> <context> $ 49 million, respectively, is primarily attributable to the difference between the amount for which the Company purchased its interest in certain joint ventures and the historical carrying value of the net assets of the related joint v... | us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity |
On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Partner share in key decisions of the assets through their voting rights, resulting in t... | text | 30 | percentItemType | text: <entity> 30 </entity> <entity type> percentItemType </entity type> <context> On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Partn... | us-gaap:EquityMethodInvestmentOwnershipPercentage |
On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Partner share in key decisions of the assets through their voting rights, resulting in t... | text | seven | integerItemType | text: <entity> seven </entity> <entity type> integerItemType </entity type> <context> On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Pa... | us-gaap:NumberOfRealEstateProperties |
On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Partner share in key decisions of the assets through their voting rights, resulting in t... | text | 126 | monetaryItemType | text: <entity> 126 </entity> <entity type> monetaryItemType </entity type> <context> On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Par... | us-gaap:ProceedsFromRealEstateAndRealEstateJointVentures |
On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Partner share in key decisions of the assets through their voting rights, resulting in t... | text | 70 | percentItemType | text: <entity> 70 </entity> <entity type> percentItemType </entity type> <context> On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Partn... | us-gaap:EquityMethodInvestmentOwnershipPercentage |
On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Partner share in key decisions of the assets through their voting rights, resulting in t... | text | 311 | monetaryItemType | text: <entity> 311 </entity> <entity type> monetaryItemType </entity type> <context> On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Par... | us-gaap:DeconsolidationGainOrLossAmount |
In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and the JV Partner share in key decisions of the assets through their voting rights, resul... | text | 65 | percentItemType | text: <entity> 65 </entity> <entity type> percentItemType </entity type> <context> In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and the... | us-gaap:EquityMethodInvestmentOwnershipPercentage |
In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and the JV Partner share in key decisions of the assets through their voting rights, resul... | text | two | integerItemType | text: <entity> two </entity> <entity type> integerItemType </entity type> <context> In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and th... | us-gaap:NumberOfRealEstateProperties |
In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and the JV Partner share in key decisions of the assets through their voting rights, resul... | text | 128 | monetaryItemType | text: <entity> 128 </entity> <entity type> monetaryItemType </entity type> <context> In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and t... | us-gaap:ProceedsFromRealEstateAndRealEstateJointVentures |
In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and the JV Partner share in key decisions of the assets through their voting rights, resul... | text | 35 | percentItemType | text: <entity> 35 </entity> <entity type> percentItemType </entity type> <context> In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and the... | us-gaap:EquityMethodInvestmentOwnershipPercentage |
In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and the JV Partner share in key decisions of the assets through their voting rights, resul... | text | 78 | monetaryItemType | text: <entity> 78 </entity> <entity type> monetaryItemType </entity type> <context> In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and th... | us-gaap:DeconsolidationGainOrLossAmount |
On the Closing Date of the Merger, the Company acquired intangible assets of $ 891 million, inclusive of $ 852 million of lease-up intangibles and $ 39 million of above market lease intangibles. Also on the Closing Date of the Merger, the Company assumed intangible liabilities of $ 150 million | text | 891 | monetaryItemType | text: <entity> 891 </entity> <entity type> monetaryItemType </entity type> <context> On the Closing Date of the Merger, the Company acquired intangible assets of $ 891 million, inclusive of $ 852 million of lease-up intangibles and $ 39 million of above market lease intangibles. Also on the Closing Date of the Merger, ... | us-gaap:FinitelivedIntangibleAssetsAcquired1 |
During the year ended December 31, 2023, in conjunction with the Company’s acquisition of real estate, the Company acquired $ 0.5 million of intangible assets with a weighted average amortization period at acquisition of 5 years. | text | 0.5 | monetaryItemType | text: <entity> 0.5 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2023, in conjunction with the Company’s acquisition of real estate, the Company acquired $ 0.5 million of intangible assets with a weighted average amortization period at acquisition of 5 years. </con... | us-gaap:FinitelivedIntangibleAssetsAcquired1 |
On the Closing Date of the Merger, inclusive of measurement period adjustments, the Company recognized goodwill of $ 51 million, | text | 51 | monetaryItemType | text: <entity> 51 </entity> <entity type> monetaryItemType </entity type> <context> On the Closing Date of the Merger, inclusive of measurement period adjustments, the Company recognized goodwill of $ 51 million, </context> | us-gaap:Goodwill |
On March 1, 2024, upon the consummation of the Merger, the Company assumed senior unsecured term loans in an aggregate principal amount of $ 400 million (the “2028 Term Loan”) that mature in May 2028 (see Note 3) pursuant to an amendment to a term loan agreement originally executed by the Physicians Partnership, as bor... | text | 400 | monetaryItemType | text: <entity> 400 </entity> <entity type> monetaryItemType </entity type> <context> On March 1, 2024, upon the consummation of the Merger, the Company assumed senior unsecured term loans in an aggregate principal amount of $ 400 million (the “2028 Term Loan”) that mature in May 2028 (see Note 3) pursuant to an amendme... | us-gaap:DebtInstrumentFaceAmount |
In connection with the assumption of the 2028 Term Loan, the Company acquired three related interest rate swap instruments that were redesignated as cash flow hedges as of the Closing Date. The 2028 Term Loan associated with these interest rate swap instruments is reported as fixed rate debt due to the Company having e... | text | three | integerItemType | text: <entity> three </entity> <entity type> integerItemType </entity type> <context> In connection with the assumption of the 2028 Term Loan, the Company acquired three related interest rate swap instruments that were redesignated as cash flow hedges as of the Closing Date. The 2028 Term Loan associated with these int... | us-gaap:NumberOfInterestRateDerivativesHeld |
4.44 %, inclusive of the impact of these interest rate swap instruments and amortization of the related premium. See also Note 22 for a discussion of the impact of the related interest rate swap instruments. | text | 4.44 | percentItemType | text: <entity> 4.44 </entity> <entity type> percentItemType </entity type> <context> 4.44 %, inclusive of the impact of these interest rate swap instruments and amortization of the related premium. See also Note 22 for a discussion of the impact of the related interest rate swap instruments. </context> | us-gaap:DebtInstrumentInterestRateEffectivePercentage |
Loans outstanding under the 2028 Term Loan bear interest at an annual rate equal to (i) the applicable margin, plus (ii) Daily SOFR (plus a 10 basis point adjustment related to SOFR transition). The applicable margin under the 2028 Term Loan ranges from 0.85 % to 1.65 % for Daily SOFR loans and is based on the credit r... | text | 10 | percentItemType | text: <entity> 10 </entity> <entity type> percentItemType </entity type> <context> Loans outstanding under the 2028 Term Loan bear interest at an annual rate equal to (i) the applicable margin, plus (ii) Daily SOFR (plus a 10 basis point adjustment related to SOFR transition). The applicable margin under the 2028 Term ... | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
Loans outstanding under the 2028 Term Loan bear interest at an annual rate equal to (i) the applicable margin, plus (ii) Daily SOFR (plus a 10 basis point adjustment related to SOFR transition). The applicable margin under the 2028 Term Loan ranges from 0.85 % to 1.65 % for Daily SOFR loans and is based on the credit r... | text | 0.85 | percentItemType | text: <entity> 0.85 </entity> <entity type> percentItemType </entity type> <context> Loans outstanding under the 2028 Term Loan bear interest at an annual rate equal to (i) the applicable margin, plus (ii) Daily SOFR (plus a 10 basis point adjustment related to SOFR transition). The applicable margin under the 2028 Ter... | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
Loans outstanding under the 2028 Term Loan bear interest at an annual rate equal to (i) the applicable margin, plus (ii) Daily SOFR (plus a 10 basis point adjustment related to SOFR transition). The applicable margin under the 2028 Term Loan ranges from 0.85 % to 1.65 % for Daily SOFR loans and is based on the credit r... | text | 1.65 | percentItemType | text: <entity> 1.65 </entity> <entity type> percentItemType </entity type> <context> Loans outstanding under the 2028 Term Loan bear interest at an annual rate equal to (i) the applicable margin, plus (ii) Daily SOFR (plus a 10 basis point adjustment related to SOFR transition). The applicable margin under the 2028 Ter... | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % sen... | text | 1.25 | monetaryItemType | text: <entity> 1.25 </entity> <entity type> monetaryItemType </entity type> <context> Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured not... | us-gaap:DebtInstrumentFaceAmount |
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % sen... | text | 400 | monetaryItemType | text: <entity> 400 </entity> <entity type> monetaryItemType </entity type> <context> Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured note... | us-gaap:DebtInstrumentFaceAmount |
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % sen... | text | 4.30 | percentItemType | text: <entity> 4.30 </entity> <entity type> percentItemType </entity type> <context> Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured note... | us-gaap:DebtInstrumentInterestRateStatedPercentage |
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % sen... | text | 350 | monetaryItemType | text: <entity> 350 </entity> <entity type> monetaryItemType </entity type> <context> Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured note... | us-gaap:DebtInstrumentFaceAmount |
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % sen... | text | 3.95 | percentItemType | text: <entity> 3.95 </entity> <entity type> percentItemType </entity type> <context> Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured note... | us-gaap:DebtInstrumentInterestRateStatedPercentage |
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % sen... | text | 500 | monetaryItemType | text: <entity> 500 </entity> <entity type> monetaryItemType </entity type> <context> Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured note... | us-gaap:DebtInstrumentFaceAmount |
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % sen... | text | 2.63 | percentItemType | text: <entity> 2.63 </entity> <entity type> percentItemType </entity type> <context> Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured note... | us-gaap:DebtInstrumentInterestRateStatedPercentage |
Lastly, on March 1, 2024, concurrently with the consummation of the Merger, the Company assumed $ 128 million aggregate principal of mortgage debt (see Note 3), which was secured by | text | 128 | monetaryItemType | text: <entity> 128 </entity> <entity type> monetaryItemType </entity type> <context> Lastly, on March 1, 2024, concurrently with the consummation of the Merger, the Company assumed $ 128 million aggregate principal of mortgage debt (see Note 3), which was secured by </context> | us-gaap:DebtInstrumentFaceAmount |
five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate... | text | five | integerItemType | text: <entity> five </entity> <entity type> integerItemType </entity type> <context> five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturitie... | us-gaap:NumberOfRealEstateProperties |
five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate... | text | 259 | monetaryItemType | text: <entity> 259 </entity> <entity type> monetaryItemType </entity type> <context> five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturitie... | us-gaap:DebtInstrumentCollateralAmount |
five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate... | text | 128 | monetaryItemType | text: <entity> 128 </entity> <entity type> monetaryItemType </entity type> <context> five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturitie... | us-gaap:DebtInstrumentFaceAmount |
five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate... | text | 59 | monetaryItemType | text: <entity> 59 </entity> <entity type> monetaryItemType </entity type> <context> five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities... | us-gaap:DebtInstrumentPeriodicPaymentInterest |
five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate... | text | 3.77 | percentItemType | text: <entity> 3.77 </entity> <entity type> percentItemType </entity type> <context> five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturitie... | us-gaap:LongTermDebtPercentageBearingFixedInterestRate |
five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate... | text | 69 | monetaryItemType | text: <entity> 69 </entity> <entity type> monetaryItemType </entity type> <context> five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities... | us-gaap:LongtermDebtPercentageBearingVariableInterestAmount |
five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate... | text | 7.25 | percentItemType | text: <entity> 7.25 </entity> <entity type> percentItemType </entity type> <context> five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturitie... | us-gaap:LongTermDebtPercentageBearingVariableInterestRate |
five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate... | text | 0.5 | monetaryItemType | text: <entity> 0.5 </entity> <entity type> monetaryItemType </entity type> <context> five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturitie... | us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet |
five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate... | text | one | integerItemType | text: <entity> one </entity> <entity type> integerItemType </entity type> <context> five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities... | us-gaap:NumberOfInterestRateDerivativesHeld |
related interest rate swap instrument with a notional amount of $ 36 million of variable rate mortgage debt that was redesignated as a cash flow hedge as of the Closing Date (see Note 22), which matured in October 2024. | text | 36 | monetaryItemType | text: <entity> 36 </entity> <entity type> monetaryItemType </entity type> <context> related interest rate swap instrument with a notional amount of $ 36 million of variable rate mortgage debt that was redesignated as a cash flow hedge as of the Closing Date (see Note 22), which matured in October 2024. </context> | us-gaap:DebtInstrumentFaceAmount |
On May 23, 2019, the Company executed a $ 2.5 billion unsecured revolving line of credit facility, with a maturity date of May 23, 2023 and two six-month extension options, subject to certain customary conditions. In September 2021, the Company executed an amended and restated unsecured revolving line of credit (the “R... | text | 2.5 | monetaryItemType | text: <entity> 2.5 </entity> <entity type> monetaryItemType </entity type> <context> On May 23, 2019, the Company executed a $ 2.5 billion unsecured revolving line of credit facility, with a maturity date of May 23, 2023 and two six-month extension options, subject to certain customary conditions. In September 2021, th... | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
On May 23, 2019, the Company executed a $ 2.5 billion unsecured revolving line of credit facility, with a maturity date of May 23, 2023 and two six-month extension options, subject to certain customary conditions. In September 2021, the Company executed an amended and restated unsecured revolving line of credit (the “R... | text | 3.0 | monetaryItemType | text: <entity> 3.0 </entity> <entity type> monetaryItemType </entity type> <context> On May 23, 2019, the Company executed a $ 2.5 billion unsecured revolving line of credit facility, with a maturity date of May 23, 2023 and two six-month extension options, subject to certain customary conditions. In September 2021, th... | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
On May 23, 2019, the Company executed a $ 2.5 billion unsecured revolving line of credit facility, with a maturity date of May 23, 2023 and two six-month extension options, subject to certain customary conditions. In September 2021, the Company executed an amended and restated unsecured revolving line of credit (the “R... | text | 10 | percentItemType | text: <entity> 10 </entity> <entity type> percentItemType </entity type> <context> On May 23, 2019, the Company executed a $ 2.5 billion unsecured revolving line of credit facility, with a maturity date of May 23, 2023 and two six-month extension options, subject to certain customary conditions. In September 2021, the ... | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
0.88 % and the facility fee was | text | 0.88 | percentItemType | text: <entity> 0.88 </entity> <entity type> percentItemType </entity type> <context> 0.88 % and the facility fee was </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
0.15 %. The Revolving Facility includes a feature that allows the Company to increase the borrowing capacity by an aggregate amount of up to $ 750 million, subject to securing additional commitments. At each of December 31, 2024 and 2023, the Company had no balance outstanding under the Revolving Facility. | text | 0.15 | percentItemType | text: <entity> 0.15 </entity> <entity type> percentItemType </entity type> <context> 0.15 %. The Revolving Facility includes a feature that allows the Company to increase the borrowing capacity by an aggregate amount of up to $ 750 million, subject to securing additional commitments. At each of December 31, 2024 and 20... | us-gaap:LineOfCreditFacilityCommitmentFeePercentage |
On August 22, 2022, the Company executed a term loan agreement (as amended or modified as described herein, the “Term Loan Agreement”) that provided for two senior unsecured delayed draw term loans in an aggregate principal amount of up to $ 500 million (the “2027 Term Loans”). The 2027 Term Loans were available to be ... | text | 500 | monetaryItemType | text: <entity> 500 </entity> <entity type> monetaryItemType </entity type> <context> On August 22, 2022, the Company executed a term loan agreement (as amended or modified as described herein, the “Term Loan Agreement”) that provided for two senior unsecured delayed draw term loans in an aggregate principal amount of u... | us-gaap:DebtInstrumentFaceAmount |
On August 22, 2022, the Company executed a term loan agreement (as amended or modified as described herein, the “Term Loan Agreement”) that provided for two senior unsecured delayed draw term loans in an aggregate principal amount of up to $ 500 million (the “2027 Term Loans”). The 2027 Term Loans were available to be ... | text | 250 | monetaryItemType | text: <entity> 250 </entity> <entity type> monetaryItemType </entity type> <context> On August 22, 2022, the Company executed a term loan agreement (as amended or modified as described herein, the “Term Loan Agreement”) that provided for two senior unsecured delayed draw term loans in an aggregate principal amount of u... | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
SOFR plus a margin that depends on the credit ratings of the Company’s senior unsecured long-term debt. The 2027 Term Loans also include a sustainability-linked pricing component whereby the applicable margin under the 2027 Term Loans may be reduced by 0.01 % based on the Company’s achievement of specified sustainabili... | text | 0.94 | percentItemType | text: <entity> 0.94 </entity> <entity type> percentItemType </entity type> <context> SOFR plus a margin that depends on the credit ratings of the Company’s senior unsecured long-term debt. The 2027 Term Loans also include a sustainability-linked pricing component whereby the applicable margin under the 2027 Term Loans ... | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
In August 2022, the Company entered into two forward-starting interest rate swap instruments that are designated as cash flow hedges (see Note 22). The 2027 Term Loans associated with these interest rate swap instruments are reported as fixed rate debt due to the Company having effectively established a fixed interest ... | text | two | integerItemType | text: <entity> two </entity> <entity type> integerItemType </entity type> <context> In August 2022, the Company entered into two forward-starting interest rate swap instruments that are designated as cash flow hedges (see Note 22). The 2027 Term Loans associated with these interest rate swap instruments are reported as... | us-gaap:NumberOfInterestRateDerivativesHeld |
In August 2022, the Company entered into two forward-starting interest rate swap instruments that are designated as cash flow hedges (see Note 22). The 2027 Term Loans associated with these interest rate swap instruments are reported as fixed rate debt due to the Company having effectively established a fixed interest ... | text | 3.76 | percentItemType | text: <entity> 3.76 </entity> <entity type> percentItemType </entity type> <context> In August 2022, the Company entered into two forward-starting interest rate swap instruments that are designated as cash flow hedges (see Note 22). The 2027 Term Loans associated with these interest rate swap instruments are reported a... | us-gaap:DerivativeFixedInterestRate |
On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Term Loan Agreement pursuant to which (i) the maximum incremental borrowing capacity under the Term Loan Agreement was increased from $ 1.0 billion to $ 1.5 billion, subject to securing additional commitments, (... | text | 1.0 | monetaryItemType | text: <entity> 1.0 </entity> <entity type> monetaryItemType </entity type> <context> On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Term Loan Agreement pursuant to which (i) the maximum incremental borrowing capacity under the Term Loan Agreement was increas... | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Term Loan Agreement pursuant to which (i) the maximum incremental borrowing capacity under the Term Loan Agreement was increased from $ 1.0 billion to $ 1.5 billion, subject to securing additional commitments, (... | text | 1.5 | monetaryItemType | text: <entity> 1.5 </entity> <entity type> monetaryItemType </entity type> <context> On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Term Loan Agreement pursuant to which (i) the maximum incremental borrowing capacity under the Term Loan Agreement was increas... | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Term Loan Agreement pursuant to which (i) the maximum incremental borrowing capacity under the Term Loan Agreement was increased from $ 1.0 billion to $ 1.5 billion, subject to securing additional commitments, (... | text | 750 | monetaryItemType | text: <entity> 750 </entity> <entity type> monetaryItemType </entity type> <context> On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Term Loan Agreement pursuant to which (i) the maximum incremental borrowing capacity under the Term Loan Agreement was increas... | us-gaap:DebtInstrumentFaceAmount |
4.66 %, inclusive of the impact of these interest rate swap instruments and amortization of the related debt issuance costs. | text | 4.66 | percentItemType | text: <entity> 4.66 </entity> <entity type> percentItemType </entity type> <context> 4.66 %, inclusive of the impact of these interest rate swap instruments and amortization of the related debt issuance costs. </context> | us-gaap:DebtInstrumentInterestRateEffectivePercentage |
At December 31, 2024 and 2023, the Company had $ 1.25 billion and $ 500 million, respectively, of loans outstanding under the Term Loan Agreement. | text | 1.25 | monetaryItemType | text: <entity> 1.25 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024 and 2023, the Company had $ 1.25 billion and $ 500 million, respectively, of loans outstanding under the Term Loan Agreement. </context> | us-gaap:LineOfCredit |
At December 31, 2024 and 2023, the Company had $ 1.25 billion and $ 500 million, respectively, of loans outstanding under the Term Loan Agreement. | text | 500 | monetaryItemType | text: <entity> 500 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024 and 2023, the Company had $ 1.25 billion and $ 500 million, respectively, of loans outstanding under the Term Loan Agreement. </context> | us-gaap:LineOfCredit |
In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, short-term unsecured notes with varying maturities. Amounts available under the Commercial Paper Program may be bo... | text | 150 | monetaryItemType | text: <entity> 150 </entity> <entity type> monetaryItemType </entity type> <context> In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, short-term unsecured notes wi... | us-gaap:ShortTermBorrowings |
In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, short-term unsecured notes with varying maturities. Amounts available under the Commercial Paper Program may be bo... | text | 4.65 | percentItemType | text: <entity> 4.65 </entity> <entity type> percentItemType </entity type> <context> In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, short-term unsecured notes wi... | us-gaap:DebtWeightedAverageInterestRate |
In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, short-term unsecured notes with varying maturities. Amounts available under the Commercial Paper Program may be bo... | text | 720 | monetaryItemType | text: <entity> 720 </entity> <entity type> monetaryItemType </entity type> <context> In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, short-term unsecured notes wi... | us-gaap:ShortTermBorrowings |
In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, short-term unsecured notes with varying maturities. Amounts available under the Commercial Paper Program may be bo... | text | 5.70 | percentItemType | text: <entity> 5.70 </entity> <entity type> percentItemType </entity type> <context> In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, short-term unsecured notes wi... | us-gaap:DebtWeightedAverageInterestRate |
At December 31, 2024 and 2023, the Company had senior unsecured notes outstanding with an aggregate principal balance of $ 6.7 billion | text | 6.7 | monetaryItemType | text: <entity> 6.7 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024 and 2023, the Company had senior unsecured notes outstanding with an aggregate principal balance of $ 6.7 billion </context> | us-gaap:DebtInstrumentCarryingAmount |
and $ 5.5 billion, respectively. The senior unsecured notes contain certain covenants including limitations on debt, maintenance of unencumbered assets, cross-acceleration provisions, and other customary terms. The Company believes it was in compliance with these covenants at December 31, 2024. | text | 5.5 | monetaryItemType | text: <entity> 5.5 </entity> <entity type> monetaryItemType </entity type> <context> and $ 5.5 billion, respectively. The senior unsecured notes contain certain covenants including limitations on debt, maintenance of unencumbered assets, cross-acceleration provisions, and other customary terms. The Company believes it ... | us-gaap:DebtInstrumentCarryingAmount |
During the year ended December 31, 2024, there were no issuances, repurchases, or redemptions of senior unsecured notes; however, as described above, concurrently with the consummation of the Merger, the Company assumed $ 1.25 billion aggregate principal of senior unsecured notes. | text | 1.25 | monetaryItemType | text: <entity> 1.25 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, there were no issuances, repurchases, or redemptions of senior unsecured notes; however, as described above, concurrently with the consummation of the Merger, the Company assumed $ 1.25 billion... | us-gaap:DebtInstrumentFaceAmount |
In May 2023, the Company issued $ 350 million of 5.25 % senior unsecured notes due 2032, which constituted an additional issuance of, and are treated as a single series with, the $ 400 million of senior unsecured notes due 2032 issued in January 2023. | text | 350 | monetaryItemType | text: <entity> 350 </entity> <entity type> monetaryItemType </entity type> <context> In May 2023, the Company issued $ 350 million of 5.25 % senior unsecured notes due 2032, which constituted an additional issuance of, and are treated as a single series with, the $ 400 million of senior unsecured notes due 2032 issued ... | us-gaap:DebtInstrumentFaceAmount |
In May 2023, the Company issued $ 350 million of 5.25 % senior unsecured notes due 2032, which constituted an additional issuance of, and are treated as a single series with, the $ 400 million of senior unsecured notes due 2032 issued in January 2023. | text | 5.25 | percentItemType | text: <entity> 5.25 </entity> <entity type> percentItemType </entity type> <context> In May 2023, the Company issued $ 350 million of 5.25 % senior unsecured notes due 2032, which constituted an additional issuance of, and are treated as a single series with, the $ 400 million of senior unsecured notes due 2032 issued ... | us-gaap:DebtInstrumentInterestRateStatedPercentage |
In May 2023, the Company issued $ 350 million of 5.25 % senior unsecured notes due 2032, which constituted an additional issuance of, and are treated as a single series with, the $ 400 million of senior unsecured notes due 2032 issued in January 2023. | text | 400 | monetaryItemType | text: <entity> 400 </entity> <entity type> monetaryItemType </entity type> <context> In May 2023, the Company issued $ 350 million of 5.25 % senior unsecured notes due 2032, which constituted an additional issuance of, and are treated as a single series with, the $ 400 million of senior unsecured notes due 2032 issued ... | us-gaap:DebtInstrumentFaceAmount |
In February 2025, the Company repaid $ 348 million aggregate principal amount of 3.40 % senior unsecured notes at maturity. | text | 348 | monetaryItemType | text: <entity> 348 </entity> <entity type> monetaryItemType </entity type> <context> In February 2025, the Company repaid $ 348 million aggregate principal amount of 3.40 % senior unsecured notes at maturity. </context> | us-gaap:RepaymentsOfDebt |
In February 2025, the Company repaid $ 348 million aggregate principal amount of 3.40 % senior unsecured notes at maturity. | text | 3.40 | percentItemType | text: <entity> 3.40 </entity> <entity type> percentItemType </entity type> <context> In February 2025, the Company repaid $ 348 million aggregate principal amount of 3.40 % senior unsecured notes at maturity. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
$ 356 million and $ 255 million, respectively, in aggregate principal of mortgage debt outstanding. At December 31, 2024, this mortgage debt was secured by 19 | text | 356 | monetaryItemType | text: <entity> 356 </entity> <entity type> monetaryItemType </entity type> <context> $ 356 million and $ 255 million, respectively, in aggregate principal of mortgage debt outstanding. At December 31, 2024, this mortgage debt was secured by 19 </context> | us-gaap:DebtInstrumentCarryingAmount |
$ 356 million and $ 255 million, respectively, in aggregate principal of mortgage debt outstanding. At December 31, 2024, this mortgage debt was secured by 19 | text | 255 | monetaryItemType | text: <entity> 255 </entity> <entity type> monetaryItemType </entity type> <context> $ 356 million and $ 255 million, respectively, in aggregate principal of mortgage debt outstanding. At December 31, 2024, this mortgage debt was secured by 19 </context> | us-gaap:DebtInstrumentCarryingAmount |
$ 356 million and $ 255 million, respectively, in aggregate principal of mortgage debt outstanding. At December 31, 2024, this mortgage debt was secured by 19 | text | 19 | integerItemType | text: <entity> 19 </entity> <entity type> integerItemType </entity type> <context> $ 356 million and $ 255 million, respectively, in aggregate principal of mortgage debt outstanding. At December 31, 2024, this mortgage debt was secured by 19 </context> | us-gaap:NumberOfRealEstateProperties |
outpatient medical buildings and 2 CCRCs, with an aggregate carrying value of | text | 2 | integerItemType | text: <entity> 2 </entity> <entity type> integerItemType </entity type> <context> outpatient medical buildings and 2 CCRCs, with an aggregate carrying value of </context> | us-gaap:NumberOfRealEstateProperties |
At December 31, 2023, this mortgage debt was secured by 15 outpatient medical buildings and 2 CCRCs, with an aggregate carrying value of $ 587 million. | text | 15 | integerItemType | text: <entity> 15 </entity> <entity type> integerItemType </entity type> <context> At December 31, 2023, this mortgage debt was secured by 15 outpatient medical buildings and 2 CCRCs, with an aggregate carrying value of $ 587 million. </context> | us-gaap:NumberOfRealEstateProperties |
At December 31, 2023, this mortgage debt was secured by 15 outpatient medical buildings and 2 CCRCs, with an aggregate carrying value of $ 587 million. | text | 2 | integerItemType | text: <entity> 2 </entity> <entity type> integerItemType </entity type> <context> At December 31, 2023, this mortgage debt was secured by 15 outpatient medical buildings and 2 CCRCs, with an aggregate carrying value of $ 587 million. </context> | us-gaap:NumberOfRealEstateProperties |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.